We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Manufacturing Issues Result in CRL for Venatorx cUTI Drug
Manufacturing Issues Result in CRL for Venatorx cUTI Drug
In a slowdown for Venatorx Pharmaceuticals, Melinta Therapeutics and the progress of new treatment for adults with complicated urinary tract infections (cUTI), the FDA issued a Complete Response Letter (CRL) for the companies’ NDA for cefepime-taniborbactam.